Western big pharma’s continues growing dependence on Chinese biotechs for drug discovery

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates.

China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump’s administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo.

Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData.

Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024.

Continue at: https://www.pharmaceutical-technology.com/news/astrazeneca-taps-chinese-biotech-in-5-2bn-chronic-disease-research-deal/?utm_source=email_NS&utm_medium=email&utm_content=Spotlight_News_Article&utm_campaign=type3_Pharmaceutical%20Technology-market&cf-view&cf-view

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:

www.manostaxx.com